Mintz Life Sciences Co-Chair, William Whelan was quoted in Fierce Pharma discussing the FTC's increasing intervention in life sciences M&A. Commenting on the FTC's interference in a recent deal involving JAB Capital Partners, Bill commented that 'typically, this kind of private equity sponsored roll up transaction has not been targeted'. He said, "That was a new twist on antitrust enforcement". 

Source

Fierce Pharma